Overview
Overview
GHK-Cu (glycyl-L-histidyl-L-lysine:copper complex) is a naturally occurring copper peptide with documented roles in wound healing, tissue remodeling, and skin regeneration[1][2]. Research demonstrates activity in gene regulation related to collagen synthesis, antioxidant defense, and anti-inflammatory pathways[3][4]. This educational protocol presents practical subcutaneous administration approaches based on clinical practice patterns. Reconstitute: Add 3.0 mL sterile water → 16.67 mg/mL concen
- Category
- Healing
- Routes
- subcutaneous, topical
Mechanism
GHK-Cu
Mechanism of action
Mechanism of action
GHK-Cu does two things at once. It carries copper into cells where copper-dependent enzymes need it, and the GHK fragment itself acts as a signaling peptide that influences gene expression in fibroblasts and other tissue cells. That dual role is part of why the research base touches so many systems: skin, hair follicles, wound beds, lung, gut, and bone in animal and cell models. Mechanistically, GHK-Cu has been shown to stimulate collagen and elastin synthesis in dermal fibroblasts, increase decorin (a small proteoglycan that helps regulate collagen organization), and influence matrix metalloproteinases and their inhibitors. Broad gene-mapping work led by Pickart and colleagues reported modulation of thousands of genes, with roughly a third of human gene patterns shifting toward expression states associated with younger or healthier tissue. The mechanism story is broad, but most of it is built on cell and animal models. The strongest human-level translation is in topical skin biology. Injectable systemic translation is still mostly indirect.
Key research findings
- 01
Identity: the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine (copper tripeptide-1), a molecule that occurs naturally in human plasma, saliva, and urine; plasma levels are reported to decline with age.
- 02
In vitro: studies report stimulation of collagen, elastin, and glycosaminoglycan synthesis by dermal fibroblasts.
- 03
Animal model: rodent and porcine wound studies report improved wound closure and tissue remodeling.
- 04
In vitro: gene-expression analyses report broad modulation of genes related to tissue remodeling and antioxidant response.
- 05
Human study (topical/cosmetic): small dermatology/cosmetic studies report effects on skin appearance and barrier; these are limited in size and scope.
Primary source: Strongest human evidence (topical): The Leyden 2002 photoaging trial in 71 women applied a GHK-Cu facial cream for 12 weeks and reported measurable improvements in skin density, thickness, fine lines, and laxity. A companion eye-cream study in 41 women compared GHK-Cu cream to placebo and vitamin K and reported greater periorbital improvement. Recent human topical evidence: A 2023 IRB-approved 21-woman topical trial of NEEL gel (a stabilized GHK-Cu topical) reported an average 28% increase in skin collagen density at 3 months, with a top quartile reporting 51%. Mechanism and gene expression: Pickart and colleagues used Broad Institute Connectivity Map data to show GHK-Cu modulates expression of more than 4,000 human genes, with shifts toward patterns associated with younger tissue. This is mechanism evidence, not outcome evidence. Preclinical wound healing: Animal wound-healing studies in rats, mice, rabbits, and pigs reported faster wound contraction, increased collagen, and improved angiogenesis with GHK-Cu, including systemic effects when GHK-Cu was injected at one site and improved healing at distant sites. Evidence gaps: No published human randomized trial has evaluated injectable GHK-Cu for cosmetic, hair, or wound endpoints. No long-term safety trial exists for injectable use. Topical strength does not automatically transfer to injectable strength.
Pharmacokinetic profile
Single-dose plasma curve over 24h. Shaded band = commonly-cited therapeutic window. Illustrative only.
Protocol Reference
Protocol reference
Commonly cited research range: 1–3 mg, daily.
Reference figures reported in the research literature — not a dosing recommendation. For interactive vial math and scheduling, see the Calculator and Schedule tabs.
Cited protocol & reconstitution guide
Source-backed reference fields by phase, including any volume fields authored in the cited guide.
Weeks 1–4 (Conservative start)
1.0 mg
Weeks 5–10 (Standard)
1.0–1.5 mg
Weeks 11–18 (Higher end)
1.5–2.0 mg
| Phase | Reference amount | Units / volume |
|---|---|---|
| Weeks 1–4 (Conservative start) | 1.0 mg | 4 units (0.04 mL) |
| Weeks 5–10 (Standard) | 1.0–1.5 mg | 4–6 units (0.04–0.06 mL) |
| Weeks 11–18 (Higher end) | 1.5–2.0 mg | 6–8 units (0.06–0.08 mL) |
Titration protocol
- Weeks 1–4Start1.0 mg, 5 days on / 2 off
Conservative start cycle (4 weeks). Rotate subcutaneous injection sites across the abdomen, outer thigh, and back of the upper arm.
- Weeks 5–10Build1.0–1.5 mg daily
Standard cycle (4–6 weeks). Rotate injection sites; a 2–4 week off-period between cycles is commonly included.
- Weeks 11–18Maintenance1.5–2.0 mg daily
Higher-end cycle (6–8 weeks); 2.0 mg/day is the high end most references cite. Rotate injection sites; a 2–4 week off-period between cycles is commonly included.
Storage & Handling
Storage requirements(typical for most peptides)
Can be stored for extended periods. Protect from moisture.
Store in refrigerator door. Never freeze after reconstitution.
Label vials with reconstitution date. Discard if cloudy.
Reconstitution steps
- 01🌡️Inspect the vial: check label, supplier, and lot number. Lyophilized GHK-Cu often appears off-white to pale blue depending on copper content and supplier process.
- 02🧴Prepare your supplies: one bacteriostatic water vial, one syringe for reconstitution, one syringe for the dose, and at least two alcohol swabs.
- 03💉Swab both stoppers: wipe the bacteriostatic water stopper and the GHK-Cu vial stopper with alcohol swabs and let them dry.
- 04💧Draw 2 mL bacteriostatic water into a sterile syringe — this 50 mg vial yields 25 mg/mL.
- 05🔄Inject down the side of the vial: aim the water against the inner glass wall, not directly onto the powder, to protect the peptide from foaming and shear.
- 06🏷️Swirl, do not shake: roll the vial gently between your hands until the powder fully dissolves. The solution should look clear with a faint blue tint from the copper complex.
- 07❄️Store under refrigeration: keep reconstituted GHK-Cu at 2–8 °C (35.6–46.4 °F), protected from light, and use within the supplier-stated beyond-use window.
- 08💉Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.
Additional storage notes
Store at −20 °C (−4 °F) or lower in dry, dark conditions [7] [8] . Keep vial tightly sealed with desiccant if possible to minimize moisture exposure.
Refrigerate at 2–8 °C (35.6–46.4 °F) and use within 30 days for optimal potency [9] . Bacteriostatic water helps inhibit bacterial growth.
For longer storage, divide solution into sterile vials and freeze at −20 °C (−4 °F) [10] . Avoid repeated freeze–thaw cycles as they degrade peptides over time [11] .
Allow vials to reach room temperature before opening to reduce condensation.
Clinical Evidence
Clinical evidence
Research shows improved wound healing, skin regeneration, hair growth, and anti-aging effects. Modulates gene expression.
Strongest human evidence (topical): The Leyden 2002 photoaging trial in 71 women applied a GHK-Cu facial cream for 12 weeks and reported measurable improvements in skin density, thickness, fine lines, and laxity. A companion eye-cream study in 41 women compared GHK-Cu cream to placebo and vitamin K and reported greater periorbital improvement. Recent human topical evidence: A 2023 IRB-approved 21-woman topical trial of NEEL gel (a stabilized GHK-Cu topical) reported an average 28% increase in skin collagen density at 3 months, with a top quartile reporting 51%. Mechanism and gene expression: Pickart and colleagues used Broad Institute Connectivity Map data to show GHK-Cu modulates expression of more than 4,000 human genes, with shifts toward patterns associated with younger tissue. This is mechanism evidence, not outcome evidence. Preclinical wound healing: Animal wound-healing studies in rats, mice, rabbits, and pigs reported faster wound contraction, increased collagen, and improved angiogenesis with GHK-Cu, including systemic effects when GHK-Cu was injected at one site and improved healing at distant sites. Evidence gaps: No published human randomized trial has evaluated injectable GHK-Cu for cosmetic, hair, or wound endpoints. No long-term safety trial exists for injectable use. Topical strength does not automatically transfer to injectable strength.
- 01Identity: the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine (copper tripeptide-1), a molecule that occurs naturally in human plasma, saliva, and urine; plasma levels are reported to decline with age.
- 02In vitro: studies report stimulation of collagen, elastin, and glycosaminoglycan synthesis by dermal fibroblasts.
- 03Animal model: rodent and porcine wound studies report improved wound closure and tissue remodeling.
- 04In vitro: gene-expression analyses report broad modulation of genes related to tissue remodeling and antioxidant response.
- 05Human study (topical/cosmetic): small dermatology/cosmetic studies report effects on skin appearance and barrier; these are limited in size and scope.
Evidence maturity varies by compound; much peptide research is preclinical (in vitro or animal-model). Where human data are limited, findings should be read as research observations, not clinical conclusions.
References
Literature references
Published research articles and sources related to GHK-Cu.
- 01Journal of Dermatological Science — GHK-Cu stimulates collagen synthesis in dermal fibroblasts and wound healing processes View Source
- 02Wound Repair and Regeneration (Wiley) — Copper peptides in wound healing: tissue remodeling and collagen gene expression View Source
- 03International Journal of Molecular Sciences (PMC) — Regenerative and protective actions of GHK-Cu: gene regulation analysis View Source
- 04Biomaterials (Elsevier) — GHK modulation of metalloproteinases and tissue inhibitors in wound healing View Source
- 05Dr Oracle AI — Clinical dosing patterns for GHK-Cu (1–2 mg subcutaneous protocols) View Source
- 06Salhab Pharmacy (Compounding Guidelines) — GHK-Cu injection protocols: 5 days/week and 3×/week dosing patterns View Source
- 07GenScript — Peptide storage and handling guidelines: lyophilized storage at −20 °C (−4 °F) View Source
- 08Peptide Sciences — Peptide storage best practices: temperature, humidity, and light protection View Source
- 09Happy Hormones MD (PDF) — GHK-Cu patient information: reconstituted storage at 2–8 °C (35.6–46.4 °F), 30-day use window View Source
- 10Tocris Bioscience — Stability and storage: aliquoting peptide solutions to minimize freeze-thaw damage View Source
- 11GenScript — Avoiding repeated freeze-thaw cycles to prevent peptide degradation View Source
- 12Roswell Park Comprehensive Cancer Center — Injection site rotation to prevent lipodystrophy and local irritation View Source
- 13Roswell Park Comprehensive Cancer Center — Subcutaneous injection site selection: abdomen, thighs, upper arms View Source
- 14Roswell Park Comprehensive Cancer Center — Proper skin preparation: alcohol swab cleaning and air-drying before injection View Source
- 15International Journal of Molecular Sciences (PMC) — Preclinical studies: GHK-Cu activity at low doses (~0.5 mcg/kg in rats) View Source
- 16Brain Sciences (MDPI) — GHK effect on gene expression relevant to nervous system function and cognitive decline View Source
- 17CDC — Vaccine administration: subcutaneous injection technique (angle, no aspiration) View Source
- 18CDC (Subcutaneous Injection PDF) — Technique diagram and site guidance for subcutaneous injections View Source
- 19NCBI Bookshelf — Best practices for injection: asepsis, preparation, administration, and sharps disposal View Source
- 20Pure Lab Peptides — GHK-Cu (50 mg) product page: quality documentation and batch testing View Source
Observed Effects
Observed effects in cited research
Topical effects
- Most reported topical effects are mild and local: redness, tingling, dryness, or transient irritation at the application site, typically more common with concentrations above 4%. Combining GHK-Cu with strong actives like high-strength retinoids or low-pH acids in the same routine can increase irritation. Most cosmetic sources recommend rotating actives instead of layering them.
Injectable effects
- Reported injectable effects are mostly local: redness, mild swelling, transient warmth, or a slight blue-tinted bruise from the copper complex. Systemic effects are rare in user reports but are not well characterized in published trials.
Theoretical risks
- Long-term or high-frequency use raises theoretical concerns about copper accumulation. GHK-Cu also stimulates both collagen synthesis and matrix metalloproteinases that break collagen down, so unbalanced or excessive use could in principle disrupt extracellular-matrix homeostasis. These risks are theoretical, not documented in human trials, but they are reasons community references include cycle off-periods.
Quality-control risk
- Research-use peptide vials vary in purity, copper content, and reconstitution stability. A trustworthy COA from an independent lab is the best buyer-side check. Avoid vials with no batch-matched COA, no copper content data, or unclear supplier provenance.
Research Considerations
Research considerations
Generally well-tolerated. Can cause mild irritation topically. Consult healthcare provider.
- GHK-Cu is most often discussed by adults exploring skin-quality, hair-quality, or tissue-repair research, especially in the context of age-related collagen decline. The topical route has the broadest applicability and the longest cosmetic safety record.
- Pregnancy and breastfeeding: GHK-Cu has not been adequately studied in pregnancy or lactation. Avoid both injectable and topical use in these populations without clinician oversight.
- Active cancer or untreated solid tumors: GHK-Cu modulates angiogenesis and gene expression. Effects in active malignancy are not well characterized, and most clinicians treat this as an exclusion until more data exists.
- Wilson's disease or other copper-handling disorders: GHK-Cu delivers bioavailable copper. Anyone with a known copper metabolism disorder should not use GHK-Cu.
- Allergy to copper: rare but possible. Test small topical patches before broader application.
- Active skin infection at the application or injection site: defer use until the area is healed.
Factors noted in the research literature; not patient-specific medical advice.
Regulatory Status
Regulatory status
RUO
Comparisons
Comparisons
| Compound | Mechanism | Route | Status |
|---|---|---|---|
| GHK-Cuthis | Stimulates collagen and glycosaminoglycan synthesis, promotes angiogenesis, and acts as antioxidant and anti-inflammatory agent. | subcutaneous, topical | Investigational / RUO |
| KPV | A C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone (Lys-Pro-Val) studied for anti-inflammatory activity, proposed to act through intracellular pathways (e.g., NF-kB modulation) without melanocortin pigmentary activity. | subcutaneous | Investigational / RUO |
| LL-37 | The sole human cathelicidin-derived cationic antimicrobial peptide (37 residues), studied for broad-spectrum antimicrobial activity, immune modulation, and roles in wound healing and angiogenesis. | subcutaneous | Investigational / RUO |
| MGF | A splice variant of IGF-1 (IGF-1Ec) produced in response to mechanical stress; its unique C-terminal E-peptide is studied for activation of muscle satellite cells and tissue repair. | subcutaneous | Investigational / RUO |
| PEG MGF | A pegylated form of mechano growth factor designed for extended stability and systemic half-life; the C-terminal E-peptide is studied for satellite-cell activation and muscle repair. | subcutaneous | Investigational / RUO |
| GHRP-2 | A synthetic hexapeptide that activates the ghrelin/GHS receptor (GHS-R1a) to stimulate dose-dependent growth hormone release; it also mildly engages prolactin and cortisol pathways. | subcutaneous | Investigational / RUO |
| GHRP-6 | A synthetic hexapeptide GH secretagogue that binds the ghrelin receptor (GHS-R1a) to stimulate pulsatile GH release and appetite via central ghrelin signaling. | subcutaneous | Investigational / RUO |
Attributes shown for research comparison only; not a statement of efficacy or therapeutic equivalence.
FAQ
Frequently asked questions
GHK-Cu is a small peptide made of three amino acids (glycine, histidine, lysine) bound to a copper ion. It occurs naturally in human plasma and was first isolated in 1973 by Loren Pickart. Plasma levels decline with age, which is part of why it became a research target for skin, hair, and wound healing.
No. GHK-Cu is not an FDA-approved drug. The topical cosmetic form (Copper Tripeptide-1) is regulated as a cosmetic ingredient. Injectable GHK-Cu was placed on the FDA's Category 2 list in 2023 and removed on April 15, 2026 because the nominations were withdrawn. The FDA announced PCAC review before the end of February 2027 for potential 503A bulks listing.
Community-derived research planning typically uses 1-2 mg per day subcutaneous for injectable workflows and 1-3% topical formulations. This is an educational reference, not a personal dosing recommendation. No human randomized trial has confirmed an optimal injectable dose.
The strongest human clinical evidence is for topical use, including the Leyden 2002 photoaging trial and a 2023 NEEL gel topical study reporting an average 28% increase in skin collagen density at 3 months. Injectable evidence is mostly preclinical and community-derived. Topical is the more evidence-supported route, especially for skin endpoints.
A common pattern is a 50 mg vial reconstituted with 2.0 mL bacteriostatic water, producing 25 mg/mL. A 1 mg dose then equals 0.04 mL, or 4 units on a U-100 insulin syringe. Adjust BAC water volume to make the draw easy to read on your syringe.
Topical effects are usually mild and local: redness, tingling, dryness, or transient irritation, more common above 4% concentration. Injectable effects are typically local: redness, mild swelling, or a slight blue-tinted bruise from the copper complex. Long-term safety in injectable use is not well characterized in published trials.
Topical trials measured skin endpoints at 8-12 weeks. The 2023 NEEL gel IRB study reported collagen-density change at 3 months. Injectable timelines are not trial-validated. Community planning typically uses 4-8 week cycles to allow time for skin or hair changes to become visible.
GHK-Cu, BPC-157, and TB-500 are commonly combined in the GLOW stack , an informal community blend. No direct stack RCT has evaluated the combination in humans. Compound-level evidence does not automatically validate the blend.
The GLOW stack is a community-derived blend of GHK-Cu, BPC-157, and TB-500 used for combined skin and recovery research. It is not an FDA-approved product and has not been studied as a fixed-ratio combination in human trials.
GHK-Cu should be avoided during pregnancy or breastfeeding, in active cancer or untreated solid tumors, in Wilson's disease or other copper-handling disorders, and in known copper allergy. Anyone with a serious medical condition should speak with a qualified clinician before considering use.
No. This page is an educational research reference. Dosing context describes common community-derived research planning, not a personal protocol. Speak with a qualified clinician before any peptide use.
Research-use notice
Research Use Only. This educational content and calculation support is intended for private research documentation. It does not provide medical advice, human-use directions, or claims of safety or effectiveness.